TRIM63 as a biomarker for MiT family RCC

In this episode Dr. Rohit Mehra of University of Michigan discusses the utility of TRIM63 as a diagnostic marker to distinguish MiTF-RCC from other renal tumor subtypes with overlapping morphology. In combination with TFE3/TFEB FISH, TRIM63 RNA-ISH assays can improve the accuracy and efficiency of MiTF-RCC diagnosis.

Study by Mehra et al, TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Modern Pathology, 34, 1596-1607, 2021. https://www.nature.com/articles/s41379-021-00803-z.


Hosted on Acast. See acast.com/privacy for more information.

More from ModPath Chat

  1. 17:47Morphologic Feature Guiding Discovery of Driver Genetic Alteration in Rare EntityNov 24, 2022
  2. 25:54Risk Stratification for SLNB in MelanomaNov 10, 2022
  3. 29:59Flat urothelial lesions of the urinary bladder: Who is in who is out?Oct 27, 2022
  4. 17:54Radio-Resistant Prostate Carcinoma: “Cribriform” morphologies and DNA Damage Response and Repair defectsOct 13, 2022
  5. 17:58The Stanford Experience in Implementation of the Molecular Classification of Endometrial carcinomas (EC)Sep 29, 2022
  6. 21:19Expanding the clinico-pathological spectrum of SDH Deficient RCCSep 15, 2022
  7. 22:01High Risk and Selected Benign Breast Lesions on Core Biopsy: Excision Vs Surveillance?Sep 01, 2022
  8. 21:31Are ancillary studies of any utility in risk assessment of Barrett’s esophagus and dysplasia?Aug 18, 2022
  9. 17:55Ki-67 assessment in pancreatic neuroendocrine neoplasms manual vs. digital?Aug 04, 2022
  10. 15:21Heterogeneity of molecular alterations in CRC with peritoneal carcinomatosisJul 21, 2022